The ROE as of November 2024 (TTM) for Relay Therapeutics, Inc. (RLAY) is -45.75%

According to Relay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -45.75%. This represents a change of 297.41% compared to the average of -11.51% of the last 4 quarters.

Relay Therapeutics, Inc. (RLAY) Historical ROE (quarterly & annually)

How has RLAY ROE performed in the past?

The mean historical ROE of Relay Therapeutics, Inc. over the last ten years is -8.86%. The current -45.75% ROE has changed 416.39% with respect to the historical average. Over the past ten years (40 quarters), RLAY's ROE was at its highest in in the December 2019 quarter at 13.25%. The ROE was at its lowest in in the June 2021 quarter at -31.27%.

Relay Therapeutics, Inc. (RLAY) ROE by Quarter and Year

Discovering the peaks and valleys of Relay Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Relay Therapeutics, Inc. (RLAY) Average ROE

How has RLAY ROE performed in the past?

The current ROE of Relay Therapeutics, Inc. (RLAY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Relay Therapeutics, Inc. (RLAY) ROE vs. Peers

How is RLAY’s ROE compared to its peers?

Relay Therapeutics, Inc.’s ROE is greater than Stoke Therapeutics, Inc. (-54.45%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Arvinas, Inc. (-50.26%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than aTyr Pharma, Inc. (-56.83%), greater than Century Therapeutics, Inc. (-66.58%), greater than Blueprint Medicines Corporation (-47.66%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Nurix Therapeutics, Inc. (-63.39%), less than Foghorn Therapeutics Inc. (167.93%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Cullinan Oncology, Inc. (-26.54%),

Build a custom stock screener for Relay Therapeutics, Inc. (RLAY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Relay Therapeutics, Inc. (RLAY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Relay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.